← Back to Screener
Arbutus Biopharma Corporation Common Stock (ABUS)
Price$4.48
Value ScoreC
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-7.36%
Price vs S&P 500 (4W)0.58%
VGM Score67.76
Market Capitalization$900.77M
All Metrics
Book Value / Share (Quarterly)$1.32
P/TBV (Annual)2.38x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.80%
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)-16.13%
Net Profit Margin (TTM)83.95%
EPS (TTM)$0.82
10-Day Avg Trading Volume1.82M
EPS Excl Extra (TTM)$0.82
Revenue Growth (5Y)15.30%
EPS (Annual)$-0.17
ROI (Annual)-41.87%
Net Profit Margin (5Y Avg)-528.86%
Cash / Share (Quarterly)$0.48
P/E Basic Excl Extra (TTM)5.60x
Revenue Growth QoQ (YoY)10054.54%
ROA (Last FY)-35.41%
Revenue Growth TTM (YoY)2889.93%
EBITD / Share (TTM)$0.81
ROE (5Y Avg)-56.00%
Operating Margin (TTM)81.72%
Cash Flow / Share (Annual)$-0.21
P/B Ratio3.46x
P/B Ratio (Quarterly)3.41x
Net Income / Employee (Annual)$-1,763,200
EV / Revenue (TTM)4.60x
Net Interest Coverage (TTM)-26.93x
ROA (TTM)112.24%
EV / EBITDA (TTM)5.63x
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)15.73x
Quick Ratio (Quarterly)53.92x
3-Month Avg Trading Volume2.06M
52-Week Price Return32.56%
P/E Incl Extra (TTM)5.60x
Revenue / Employee (TTM)$10,076,100
Tangible BV / Share (Quarterly)$1.12
P/S Ratio (Annual)63.96x
Asset Turnover (Annual)0.15x
52-Week High$5.10
Operating Margin (5Y Avg)-554.99%
EPS Excl Extra (Annual)$-0.17
CapEx CAGR (5Y)-20.96%
Tangible BV CAGR (5Y)23.90%
26-Week Price Return8.57%
Quick Ratio (Annual)15.47x
13-Week Price Return-2.98%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)54.26x
Enterprise Value$880.34M
Revenue / Share Growth (5Y)-4.20%
Asset Turnover (TTM)1.34x
Book Value / Share Growth (5Y)-18.95%
Revenue / Employee (Annual)$741,200
Pretax Margin (Annual)-237.88%
Cash / Share (Annual)$0.48
3-Month Return Std Dev42.52%
Net Income / Employee (TTM)$8,458,900
ROE (Last FY)-43.75%
Net Interest Coverage (Annual)-37.59x
EPS Basic Excl Extra (Annual)$-0.17
P/FCF (TTM)43.85x
Receivables Turnover (TTM)2.11x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$0.82
Receivables Turnover (Annual)7.30x
ROI (TTM)125.70%
P/S Ratio (TTM)4.71x
Pretax Margin (5Y Avg)-526.58%
Revenue / Share (Annual)$0.07
Tangible BV / Share (Annual)$1.12
Forward P/E33.01x
Price vs S&P 500 (52W)4.35%
P/E Ratio (TTM)5.60x
Year-to-Date Return-5.20%
5-Day Price Return4.83%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-42.36%
Net Profit Margin (Annual)-237.88%
Month-to-Date Return8.57%
Cash Flow / Share (TTM)$-0.46
EBITD / Share (Annual)$-0.20
Operating Margin (Annual)-270.96%
LT Debt / Equity (Annual)0.04x
ROI (5Y Avg)-54.10%
P/E Excl Extra (TTM)5.60x
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$0.82
P/TBV (Quarterly)2.38x
P/B Ratio (Annual)12.08x
Pretax Margin (TTM)83.95%
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-12.72%
Beta0.62x
P/FCF (Annual)27.38x
Revenue / Share (TTM)$0.98
ROE (TTM)129.32%
52-Week Low$3.04
vGradeC
gGradeA
mGradeC
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.03
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABUSArbutus Biopharma Corporation Common Stock | C | A | C | $4.48 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing combination therapies for hepatitis B aimed at achieving a functional cure. Key pipeline candidates include imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company leverages proprietary Lipid Nanoparticle (LNP) delivery technology to optimize therapeutic efficacy.